Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.39 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922678 | 1.00 | KMT2A (0.47) | KMT2ANFE2L2MAPTLMNACYP2C19 | |
| SCHEMBL1041532 | 0.76 | MAPT (0.46) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL4136416 | 0.76 | MAPT (0.46) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL6934839 | 0.75 | MEN1 (0.57) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL6934835 | 0.75 | MEN1 (0.57) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL7248148 | 0.75 | MEN1 (0.64) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL15084622 | 0.72 | KMT2A (0.55) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL7248152 | 0.72 | MAPT (0.64) | KMT2AMAPTLMNACYP2C19MEN1 | |
| SCHEMBL3928356 | 0.72 | NFE2L2 (0.49) | KMT2ANFE2L2MAPTMEN1NPC1 | |
| SCHEMBL4364965 | 0.72 | NFE2L2 (0.46) | KMT2ANFE2L2MAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041122-B1 | AZOLYLMETHYLOXIRANES, THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203700-A1 | Azolylmethyloxiranes, Their Use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them | BASF SE (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009077497-A2 | AZOLYL METHYL OXIRANES, THE USE THEREOF, AND AGENTS CONTAINING THEM | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2041122-A1 | AZOLYLMETHYLOXIRANES, THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF SE (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003622-A1 | AZOLYLMETHYLOXIRANES, THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF SE (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203700-A1 | Azolylmethyloxiranes, Their Use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them | CBR3, NAT1, C5 | KMT2A 1226/4885NFE2L2 1164/4885MAPT 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.